Vol. 41 | Vol. 41(6) - November / December 2023 | COLUMN: Start-Ups Innovation

Tailor-made enzyme solutions for production processes of biologics

by 4 December 2023

R. Correro 4 December 2023

ADCs

biologics

Continuous manufacturing

Enzymes

in-vitro transcription

mRNA

RITA CORRERO
INOFEA AG

Context/Overview
Biologics, including mRNA-based therapeutics/vaccines and antibody drug conjugates (ADCs), have demonstrated groundbreaking benefits in healthcare, offering not only preventive measures against viral infections but also targeted therapies with reduced side effects for cancer and autoimmune diseases. Nevertheless, the manufacturing of such Biologics is a sophisticated process with still several challenges to address.

ABOUT THE AUTHOR

Rita Correro – CTO, Biochemist by education, after her PhD at the ETH Zurich, Rita has joined the Institute for Chemistry and Bioanalytics at the FHNW as postdoctoral fellow. During this time, she has developed the methodology of enzyme immobilization and shielding which is the core technology of INOFEA.

Sparsentan

Latest issue

Vol. 44(4) – July / August 2026

View Issue

Content from magazine

“Contents from Magazine” offers curated articles and insights from the field of chemistry, focused on research, data, and scientific developments

View all content

Tailor-made enzyme solutions for production processes of biologics

You may also like

The importance of investments to tackle the future challenges

Peptide-based nanoparticles for extrahepatic delivery of therapeutic R...

YMC – Improved Oligo and Peptide Purification using next generat...

Assuring quality of oligonucleotide APIs and DPs